ASAF stands for: Ablation of Sympathetic Atrial Fibrillation
Treatment of atrial fibrillation in patients with high sympathetic activity by pulmonary vein isolation in combination with renal denervation or pulmonary vein isolation only; an international randomized, controlled trial
The trial is designed to:
- Investigate if renal denervation in combination with pulmonary vein isolation prevents atrial fibrillation in patients with out of range hypertension or signs of sympathetic overdrive
- Investigate if renal denervation in combination with pulmonary vein isolation, is more successful in achieving long term sinus rhythm than pulmonary vein isolation alone in patients with atrial fibrillation and out of range hypertension or signs of sympathetic overdrive
The physician-initiated, prospective, multicenter, randomized trial is currently enrolling 138 patients in centers in The Netherlands and Spain.
The primary endpoint is time to first detection of atrial fibrillation >30 seconds, with the monitoring period starting 3 months after the intervention.
Principal investigator is Arif Elvan MD, PhD, Isala hospital Zwolle, The Netherlands.